Incidence of Inborn Errors of Metabolism by Expanded Newborn Screening in a Mexican Hospital

Newborn screening for the detection of inborn errors of metabolism (IEM), endocrinopathies, hemoglobinopathies, and other disorders is a public health initiative aimed at identifying specific diseases in a timely manner. Mexico initiated newborn screening in 1973, but the national incidence of this...

Full description

Bibliographic Details
Main Authors: Consuelo Cantú-Reyna MD, Luis Manuel Zepeda MD, René Montemayor MD, Santiago Benavides MD, Héctor Javier González MD, Mercedes Vázquez-Cantú BS, Héctor Cruz-Camino BS
Format: Article
Language:English
Published: SciELO 2016-09-01
Series:Journal of Inborn Errors of Metabolism and Screening
Online Access:https://doi.org/10.1177/2326409816669027
id doaj-0c081410126447028c7cee72bcd92468
record_format Article
spelling doaj-0c081410126447028c7cee72bcd924682020-11-24T21:37:06ZengSciELOJournal of Inborn Errors of Metabolism and Screening 2326-45942016-09-01410.1177/232640981666902710.1177_2326409816669027Incidence of Inborn Errors of Metabolism by Expanded Newborn Screening in a Mexican HospitalConsuelo Cantú-Reyna MD0Luis Manuel Zepeda MD1René Montemayor MD2Santiago Benavides MD3Héctor Javier González MD4Mercedes Vázquez-Cantú BS5Héctor Cruz-Camino BS6 Escuela de Medicina Tecnológico de Monterrey, Monterrey, Nuevo León, México Escuela de Medicina Tecnológico de Monterrey, Monterrey, Nuevo León, México Hospital de Ginecología y Obstetricia SA de CV Monterrey, Nuevo León, México Hospital de Ginecología y Obstetricia SA de CV Monterrey, Nuevo León, México Escuela de Medicina Tecnológico de Monterrey, Monterrey, Nuevo León, México Department of Biosystems Science and Engineering ETH Zurich, Basel, Switzerland Escuela de Biotecnología y Ciencias de la Salud, Instituto Tecnológico de Monterrey, Monterrey, MéxicoNewborn screening for the detection of inborn errors of metabolism (IEM), endocrinopathies, hemoglobinopathies, and other disorders is a public health initiative aimed at identifying specific diseases in a timely manner. Mexico initiated newborn screening in 1973, but the national incidence of this group of diseases is unknown or uncertain due to the lack of large sample sizes of expanded newborn screening (ENS) programs and lack of related publications. The incidence of a specific group of IEM, endocrinopathies, hemoglobinopathies, and other disorders in newborns was obtained from a Mexican hospital. These newborns were part of a comprehensive ENS program at Ginequito (a private hospital in Mexico), from January 2012 to August 2014. The retrospective study included the examination of 10 000 newborns’ results obtained from the ENS program (comprising the possible detection of more than 50 screened disorders). The findings were the following: 34 newborns were confirmed with an IEM, endocrinopathies, hemoglobinopathies, or other disorders and 68 were identified as carriers. Consequently, the estimated global incidence for those disorders was 3.4 in 1000 newborns; and the carrier prevalence was 6.8 in 1000. Moreover, a 0.04% false-positive rate was unveiled as soon as diagnostic testing revealed negative results. The most frequent diagnosis was glucose-6-phosphate dehydrogenase deficiency; and in the case of carriers, it was hemoglobinopathies. The benefit of the ENS is clear as it offers prompt treatment on the basis of an early diagnosis including proper genetic counseling. Furthermore, these results provide a good estimation of the frequencies of different forms of newborn IEM, endocrinopathies, hemoglobinopathies, and other disorders at Ginequito.https://doi.org/10.1177/2326409816669027
collection DOAJ
language English
format Article
sources DOAJ
author Consuelo Cantú-Reyna MD
Luis Manuel Zepeda MD
René Montemayor MD
Santiago Benavides MD
Héctor Javier González MD
Mercedes Vázquez-Cantú BS
Héctor Cruz-Camino BS
spellingShingle Consuelo Cantú-Reyna MD
Luis Manuel Zepeda MD
René Montemayor MD
Santiago Benavides MD
Héctor Javier González MD
Mercedes Vázquez-Cantú BS
Héctor Cruz-Camino BS
Incidence of Inborn Errors of Metabolism by Expanded Newborn Screening in a Mexican Hospital
Journal of Inborn Errors of Metabolism and Screening
author_facet Consuelo Cantú-Reyna MD
Luis Manuel Zepeda MD
René Montemayor MD
Santiago Benavides MD
Héctor Javier González MD
Mercedes Vázquez-Cantú BS
Héctor Cruz-Camino BS
author_sort Consuelo Cantú-Reyna MD
title Incidence of Inborn Errors of Metabolism by Expanded Newborn Screening in a Mexican Hospital
title_short Incidence of Inborn Errors of Metabolism by Expanded Newborn Screening in a Mexican Hospital
title_full Incidence of Inborn Errors of Metabolism by Expanded Newborn Screening in a Mexican Hospital
title_fullStr Incidence of Inborn Errors of Metabolism by Expanded Newborn Screening in a Mexican Hospital
title_full_unstemmed Incidence of Inborn Errors of Metabolism by Expanded Newborn Screening in a Mexican Hospital
title_sort incidence of inborn errors of metabolism by expanded newborn screening in a mexican hospital
publisher SciELO
series Journal of Inborn Errors of Metabolism and Screening
issn 2326-4594
publishDate 2016-09-01
description Newborn screening for the detection of inborn errors of metabolism (IEM), endocrinopathies, hemoglobinopathies, and other disorders is a public health initiative aimed at identifying specific diseases in a timely manner. Mexico initiated newborn screening in 1973, but the national incidence of this group of diseases is unknown or uncertain due to the lack of large sample sizes of expanded newborn screening (ENS) programs and lack of related publications. The incidence of a specific group of IEM, endocrinopathies, hemoglobinopathies, and other disorders in newborns was obtained from a Mexican hospital. These newborns were part of a comprehensive ENS program at Ginequito (a private hospital in Mexico), from January 2012 to August 2014. The retrospective study included the examination of 10 000 newborns’ results obtained from the ENS program (comprising the possible detection of more than 50 screened disorders). The findings were the following: 34 newborns were confirmed with an IEM, endocrinopathies, hemoglobinopathies, or other disorders and 68 were identified as carriers. Consequently, the estimated global incidence for those disorders was 3.4 in 1000 newborns; and the carrier prevalence was 6.8 in 1000. Moreover, a 0.04% false-positive rate was unveiled as soon as diagnostic testing revealed negative results. The most frequent diagnosis was glucose-6-phosphate dehydrogenase deficiency; and in the case of carriers, it was hemoglobinopathies. The benefit of the ENS is clear as it offers prompt treatment on the basis of an early diagnosis including proper genetic counseling. Furthermore, these results provide a good estimation of the frequencies of different forms of newborn IEM, endocrinopathies, hemoglobinopathies, and other disorders at Ginequito.
url https://doi.org/10.1177/2326409816669027
work_keys_str_mv AT consuelocantureynamd incidenceofinbornerrorsofmetabolismbyexpandednewbornscreeninginamexicanhospital
AT luismanuelzepedamd incidenceofinbornerrorsofmetabolismbyexpandednewbornscreeninginamexicanhospital
AT renemontemayormd incidenceofinbornerrorsofmetabolismbyexpandednewbornscreeninginamexicanhospital
AT santiagobenavidesmd incidenceofinbornerrorsofmetabolismbyexpandednewbornscreeninginamexicanhospital
AT hectorjaviergonzalezmd incidenceofinbornerrorsofmetabolismbyexpandednewbornscreeninginamexicanhospital
AT mercedesvazquezcantubs incidenceofinbornerrorsofmetabolismbyexpandednewbornscreeninginamexicanhospital
AT hectorcruzcaminobs incidenceofinbornerrorsofmetabolismbyexpandednewbornscreeninginamexicanhospital
_version_ 1725938200472453120